BridgeBio Pharma, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

BridgeBio Pharma will release its 2025 financial results on February 24, 2026, followed by a conference call.

Quiver AI Summary

BridgeBio Pharma, Inc. announced it will release its fourth quarter and full year 2025 financial results on February 24, 2026, after the market closes. A conference call to discuss the results and program updates will take place at 4:30 pm ET on the same day, with a live webcast available on the company's website. BridgeBio focuses on developing medicines for genetic conditions, aiming to address the lack of treatment options for small patient populations through a decentralized operational model. Interested parties can access the webcast and find more information about the company on its website and social media channels.

Potential Positives

BridgeBio Pharma is set to announce its fourth quarter and full year 2025 financial results, indicating transparency and accountability in financial reporting.
The scheduled conference call allows investors and stakeholders to receive direct updates on financial performance and business developments, fostering open communication.
BridgeBio’s commitment to developing transformative medicines for underserved patient populations highlights its focus on addressing critical healthcare needs, which can enhance its reputation and market position.

Potential Negatives

BridgeBio is set to release its financial results, which can indicate potential underperformance or financial difficulties if the results are poor.
The announcement only mentions the release date for financial results, without providing any preliminary insights or signals about performance, which may raise concerns among investors.
The focus on developing medicines for small patient populations suggests inherent challenges in profitability and sustainability of the business model.

FAQ

When will BridgeBio release its financial results for 2025?

BridgeBio will release its fourth quarter and full year 2025 financial results on February 24, 2026, after market close.

What time is BridgeBio's conference call?

The conference call to discuss the financial results and program updates will be held at 4:30 pm ET on February 24, 2026.

How can I access the BridgeBio webcast?

You can access the live webcast on the “Events & Presentations” page of the BridgeBio website at investor.bridgebio.com/events-and-presentations/.

Will there be a replay available of the webcast?

Yes, a replay of the webcast will be available on the BridgeBio website for 30 days following the event.

What is BridgeBio Pharma's mission?

BridgeBio's mission is to develop transformative medicines for genetic conditions and bridge the gap for underserved patient populations.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$BBIO Insider Trading Activity

$BBIO insiders have traded $BBIO stock on the open market 90 times in the past 6 months. Of those trades, 0 have been purchases and 90 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 71 sales selling 562,323 shares for an estimated $36,481,751.
FRANK MCCORMICK has made 0 purchases and 7 sales selling 274,000 shares for an estimated $17,246,736.
ANDREW LO has made 0 purchases and 4 sales selling 95,599 shares for an estimated $6,319,662.
RONALD J DANIELS sold 61,031 shares for an estimated $3,888,999
THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 3 sales selling 59,171 shares for an estimated $3,215,485.
HANNAH VALANTINE sold 25,484 shares for an estimated $1,683,727
RANDAL W. SCOTT has made 0 purchases and 2 sales selling 10,000 shares for an estimated $666,465.
MARICEL APULI (Chief Accounting Officer) sold 2,000 shares for an estimated $148,520

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$BBIO Congressional Stock Trading

Members of Congress have traded $BBIO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 09/22.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$BBIO Hedge Fund Activity

We have seen 244 institutional investors add shares of $BBIO stock to their portfolio, and 206 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VIKING GLOBAL INVESTORS LP removed 2,577,526 shares (-13.9%) from their portfolio in Q3 2025, for an estimated $133,876,700
MACQUARIE GROUP LTD removed 1,933,096 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $147,862,513
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,602,036 shares (-78.0%) from their portfolio in Q4 2025, for an estimated $122,539,733
WOODLINE PARTNERS LP removed 1,506,482 shares (-88.4%) from their portfolio in Q3 2025, for an estimated $78,246,675
HOOD RIVER CAPITAL MANAGEMENT LLC added 1,243,545 shares (+inf%) to their portfolio in Q3 2025, for an estimated $64,589,727
INVESCO LTD. added 1,127,592 shares (+40.3%) to their portfolio in Q3 2025, for an estimated $58,567,128
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,051,679 shares (+inf%) to their portfolio in Q3 2025, for an estimated $54,624,207

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$BBIO Analyst Ratings

Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Overweight" rating on 01/28/2026
Truist Securities issued a "Buy" rating on 01/08/2026
Morgan Stanley issued a "Overweight" rating on 01/06/2026
JP Morgan issued a "Overweight" rating on 11/07/2025
HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
Goldman Sachs issued a "Buy" rating on 10/31/2025
Raymond James issued a "Outperform" rating on 10/30/2025

To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.

$BBIO Price Targets

Multiple analysts have issued price targets for $BBIO recently. We have seen 15 analysts offer price targets for $BBIO in the last 6 months, with a median target of $94.0.

Here are some recent targets:

Raghuram Selvaraju from HC Wainwright & Co. set a target price of $100.0 on 02/17/2026
Trevor Allred from Oppenheimer set a target price of $83.0 on 02/13/2026
Derek Archila from Wells Fargo set a target price of $98.0 on 02/13/2026
Eliana Merle from Barclays set a target price of $80.0 on 01/28/2026
Danielle Brill from Truist Securities set a target price of $86.0 on 01/08/2026
Sean Laaman from Morgan Stanley set a target price of $96.0 on 01/06/2026
Mani Foroohar from Leerink Partners set a target price of $86.0 on 12/15/2025

Full Release

PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.

To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/ . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

Participants may access the webcast by registering online using the following link, here .

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn , X , Facebook , Instagram , YouTube , and TikTok .

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
[email protected]
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]